CD5-Positive B Lymphocytes after Kidney Transplantation
Kidney transplantation is the treatment of choice for end-stage kidney diseases. Unfortunately, kidney allograft recipients rarely develop tolerance or accommodation and require life-long immunosuppression. Among many other regulatory mechanisms, CD5+ B lymphocytes (mainly B-1a) seem to be involved...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/9/1574 |
| _version_ | 1797519687958921216 |
|---|---|
| author | Maciej Zieliński Agnieszka Tarasewicz Hanna Zielińska Magdalena Jankowska Justyna Sakowska Anna Dukat-Mazurek Grażyna Moszkowska Bolesław Rutkowski Alicja Dębska-Ślizień Piotr Trzonkowski |
| author_facet | Maciej Zieliński Agnieszka Tarasewicz Hanna Zielińska Magdalena Jankowska Justyna Sakowska Anna Dukat-Mazurek Grażyna Moszkowska Bolesław Rutkowski Alicja Dębska-Ślizień Piotr Trzonkowski |
| author_sort | Maciej Zieliński |
| collection | DOAJ |
| description | Kidney transplantation is the treatment of choice for end-stage kidney diseases. Unfortunately, kidney allograft recipients rarely develop tolerance or accommodation and require life-long immunosuppression. Among many other regulatory mechanisms, CD5+ B lymphocytes (mainly B-1a) seem to be involved in the process of allograft acceptance. These cells are the major source of natural, low-affinity antibodies, which are polyreactive. Thus, we hypothesized that CD5+ B cells could be referred to as a biomarker in those patients who developed accommodation towards kidney allotransplant. In this study, 52 low-immunized kidney transplant recipients were evaluated for transplant outcome up to 8 y post-transplant. The follow up included anti-HLA antibodies, B cells phenotype and cytokines. We have identified a cohort of recipients who produced alloantibodies (Abs+), which was associated with increased levels of CD5+ B cells, mainly during the first year after transplantation but also later on. Importantly, creatinine levels were comparable between Abs+ and Abs− allorecipients at 2 years after the transplantation and graft survival rate was comparable between these groups even eight years post-transplant. So, it seems that despite the presence of alloantibodies the graft function was sustained when the level of CD5+ B cells was increased. Targeting CD5+ B cells may be a valuable therapeutic option to increase transplant success. The phenotype can be also tried as a biomarker to increase the effectiveness of individualized post-transplant treatments. |
| first_indexed | 2024-03-10T07:46:20Z |
| format | Article |
| id | doaj.art-50e3d36b5aac47a7b96ef39f4140cf13 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T07:46:20Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-50e3d36b5aac47a7b96ef39f4140cf132023-11-22T12:39:02ZengMDPI AGDiagnostics2075-44182021-08-01119157410.3390/diagnostics11091574CD5-Positive B Lymphocytes after Kidney TransplantationMaciej Zieliński0Agnieszka Tarasewicz1Hanna Zielińska2Magdalena Jankowska3Justyna Sakowska4Anna Dukat-Mazurek5Grażyna Moszkowska6Bolesław Rutkowski7Alicja Dębska-Ślizień8Piotr Trzonkowski9Department of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, PolandKidney transplantation is the treatment of choice for end-stage kidney diseases. Unfortunately, kidney allograft recipients rarely develop tolerance or accommodation and require life-long immunosuppression. Among many other regulatory mechanisms, CD5+ B lymphocytes (mainly B-1a) seem to be involved in the process of allograft acceptance. These cells are the major source of natural, low-affinity antibodies, which are polyreactive. Thus, we hypothesized that CD5+ B cells could be referred to as a biomarker in those patients who developed accommodation towards kidney allotransplant. In this study, 52 low-immunized kidney transplant recipients were evaluated for transplant outcome up to 8 y post-transplant. The follow up included anti-HLA antibodies, B cells phenotype and cytokines. We have identified a cohort of recipients who produced alloantibodies (Abs+), which was associated with increased levels of CD5+ B cells, mainly during the first year after transplantation but also later on. Importantly, creatinine levels were comparable between Abs+ and Abs− allorecipients at 2 years after the transplantation and graft survival rate was comparable between these groups even eight years post-transplant. So, it seems that despite the presence of alloantibodies the graft function was sustained when the level of CD5+ B cells was increased. Targeting CD5+ B cells may be a valuable therapeutic option to increase transplant success. The phenotype can be also tried as a biomarker to increase the effectiveness of individualized post-transplant treatments.https://www.mdpi.com/2075-4418/11/9/1574B cellstolerancebiomarkerstransplantation |
| spellingShingle | Maciej Zieliński Agnieszka Tarasewicz Hanna Zielińska Magdalena Jankowska Justyna Sakowska Anna Dukat-Mazurek Grażyna Moszkowska Bolesław Rutkowski Alicja Dębska-Ślizień Piotr Trzonkowski CD5-Positive B Lymphocytes after Kidney Transplantation Diagnostics B cells tolerance biomarkers transplantation |
| title | CD5-Positive B Lymphocytes after Kidney Transplantation |
| title_full | CD5-Positive B Lymphocytes after Kidney Transplantation |
| title_fullStr | CD5-Positive B Lymphocytes after Kidney Transplantation |
| title_full_unstemmed | CD5-Positive B Lymphocytes after Kidney Transplantation |
| title_short | CD5-Positive B Lymphocytes after Kidney Transplantation |
| title_sort | cd5 positive b lymphocytes after kidney transplantation |
| topic | B cells tolerance biomarkers transplantation |
| url | https://www.mdpi.com/2075-4418/11/9/1574 |
| work_keys_str_mv | AT maciejzielinski cd5positiveblymphocytesafterkidneytransplantation AT agnieszkatarasewicz cd5positiveblymphocytesafterkidneytransplantation AT hannazielinska cd5positiveblymphocytesafterkidneytransplantation AT magdalenajankowska cd5positiveblymphocytesafterkidneytransplantation AT justynasakowska cd5positiveblymphocytesafterkidneytransplantation AT annadukatmazurek cd5positiveblymphocytesafterkidneytransplantation AT grazynamoszkowska cd5positiveblymphocytesafterkidneytransplantation AT bolesławrutkowski cd5positiveblymphocytesafterkidneytransplantation AT alicjadebskaslizien cd5positiveblymphocytesafterkidneytransplantation AT piotrtrzonkowski cd5positiveblymphocytesafterkidneytransplantation |